Berberine has an unusually consistent dose across its clinical literature: 500 mg two or three times a day with meals, totalling 0.9 to 1.5 g/day. That consistency makes formulation simple and makes deviation conspicuous. This guide sets out the dose, the purity grade behind it, the tolerability profile and the interactions a label must carry.
Quick-Reference Dosage Table
| Evidence | Dose | Material | Duration |
|---|---|---|---|
| Meta-analyses of randomised trials in type 2 diabetes (glucose and HbA1c markers) | 0.9 to 1.5 g/day, usually 500 mg two or three times daily | Berberine hydrochloride, 97% or higher | 8 to 16 weeks, some to 24 |
| Meta-analysis in dyslipidaemia | 0.9 to 1.5 g/day | Berberine hydrochloride | 8 to 12 weeks |
| Meta-analysis across metabolic syndrome components | 0.9 to 1.5 g/day | Berberine hydrochloride | 12 weeks typical |
The pooled trials report improvements in fasting glucose, HbA1c, LDL cholesterol and triglycerides against placebo or as an add-on to standard care, with heterogeneity the reviews flag as a limitation. What matters for a formulator is that every one of them used berberine as the isolated alkaloid, not a crude Berberis extract, and dosed it in divided doses with meals.
Purity Grade and Salt Form
Trade berberine is berberine hydrochloride at 97% to 98% purity by HPLC, produced from Berberis aristata or Coptis root; the sulphate is less common. A 500 mg dose of 97% material delivers about 485 mg of berberine base equivalent. Crude Berberis extracts standardised to 10% or 20% berberine are a different product and cannot reach the trial dose in a reasonable serving. Specify the salt, the purity and the botanical source; heavy metal and residual solvent limits apply because the material is a purified isolate.
Divided Dosing and Tolerability
Berberine has poor oral bioavailability and a short half-life, which is why the trials split the daily total into two or three doses taken with meals. Single 1,500 mg doses were not used. Gastrointestinal effects, mainly constipation, diarrhoea and abdominal discomfort, are the common adverse events and are dose-related; starting at 500 mg once daily for a week before stepping up is a reasonable direction for use.
Interactions and Label Warnings
- Blood-glucose-lowering medicines. Additive effect; a caution to consult a physician is standard.
- CYP3A4 and P-glycoprotein substrates. Berberine inhibits both; interactions with ciclosporin, some statins and other narrow-therapeutic-index drugs are documented.
- Pregnancy, breastfeeding and neonates. Contraindicated; berberine displaces bilirubin and has been associated with neonatal jaundice.
Formulation Notes
Berberine HCl is a bright yellow, bitter, crystalline powder that stains. Capsules are the standard format at 500 mg; tablets need a film coat for taste and colour; gummies are impractical at the trial dose. Enhanced-absorption forms (phospholipid complexes, liposomal or dihydroberberine) are marketed at lower nominal doses, but the trials above were run on plain berberine HCl, and a lower dose of a different form is not the same evidence.
The regulatory position, including novel-food and permitted-use questions by market, is covered in berberine regulatory compliance.
Berberine HCl 97%, HPLC-assayed
Pharmaceutical-grade purity with botanical source, heavy metals and residual solvent on the COA.